Cargando…
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Nature Singapore
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606053/ https://www.ncbi.nlm.nih.gov/pubmed/36166110 http://dx.doi.org/10.1007/s10147-022-02237-2 |
| _version_ | 1784818214336724992 |
|---|---|
| author | Aogi, Kenjiro Watanabe, Kenichi Kitada, Masahiro Sangai, Takafumi Ohtani, Shoichiro Aruga, Tomoyuki Kawaguchi, Hidetoshi Fujisawa, Tomomi Maeda, Shigeto Morimoto, Takashi Sato, Nobuaki Takao, Shintaro Morita, Satoshi Masuda, Norikazu Toi, Masakazu Ohno, Shinji |
| author_facet | Aogi, Kenjiro Watanabe, Kenichi Kitada, Masahiro Sangai, Takafumi Ohtani, Shoichiro Aruga, Tomoyuki Kawaguchi, Hidetoshi Fujisawa, Tomomi Maeda, Shigeto Morimoto, Takashi Sato, Nobuaki Takao, Shintaro Morita, Satoshi Masuda, Norikazu Toi, Masakazu Ohno, Shinji |
| author_sort | Aogi, Kenjiro |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9606053 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Nature Singapore |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96060532022-10-28 Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19) Aogi, Kenjiro Watanabe, Kenichi Kitada, Masahiro Sangai, Takafumi Ohtani, Shoichiro Aruga, Tomoyuki Kawaguchi, Hidetoshi Fujisawa, Tomomi Maeda, Shigeto Morimoto, Takashi Sato, Nobuaki Takao, Shintaro Morita, Satoshi Masuda, Norikazu Toi, Masakazu Ohno, Shinji Int J Clin Oncol Correction Springer Nature Singapore 2022-09-27 2022 /pmc/articles/PMC9606053/ /pubmed/36166110 http://dx.doi.org/10.1007/s10147-022-02237-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Aogi, Kenjiro Watanabe, Kenichi Kitada, Masahiro Sangai, Takafumi Ohtani, Shoichiro Aruga, Tomoyuki Kawaguchi, Hidetoshi Fujisawa, Tomomi Maeda, Shigeto Morimoto, Takashi Sato, Nobuaki Takao, Shintaro Morita, Satoshi Masuda, Norikazu Toi, Masakazu Ohno, Shinji Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19) |
| title | Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19) |
| title_full | Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19) |
| title_fullStr | Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19) |
| title_full_unstemmed | Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19) |
| title_short | Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19) |
| title_sort | correction to: clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent her2-negative breast cancer: a randomized phase ii study (jbcrg-19) |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606053/ https://www.ncbi.nlm.nih.gov/pubmed/36166110 http://dx.doi.org/10.1007/s10147-022-02237-2 |
| work_keys_str_mv | AT aogikenjiro correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 AT watanabekenichi correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 AT kitadamasahiro correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 AT sangaitakafumi correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 AT ohtanishoichiro correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 AT arugatomoyuki correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 AT kawaguchihidetoshi correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 AT fujisawatomomi correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 AT maedashigeto correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 AT morimototakashi correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 AT satonobuaki correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 AT takaoshintaro correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 AT moritasatoshi correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 AT masudanorikazu correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 AT toimasakazu correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 AT ohnoshinji correctiontoclinicalusefulnessoferibulinasfirstorsecondlinechemotherapyforrecurrenther2negativebreastcancerarandomizedphaseiistudyjbcrg19 |